doi: 10.1038/nbt0804-953.
Redesigner drugs
- PMID: 15286643
- DOI: 10.1038/nbt0804-953
Item in Clipboard
Redesigner drugs
Nat Biotechnol.
2004 Aug.
Abstract
Drug development is a risky business, and the final product can have serious, sometimes deadly flaws. But by focusing on fixing those flaws, companies are catapulting themselves to profitability.
Similar articles
-
Biotech patents-business as usual?Nat Biotechnol. 2008 Dec;26(12):1326. doi: 10.1038/nbt1208-1326. Nat Biotechnol. 2008. PMID: 19060861 No abstract available.
-
Cost-effectiveness data on biologics needed.Nat Biotechnol. 2005 Mar;23(3):272-3. doi: 10.1038/nbt0305-272. Nat Biotechnol. 2005. PMID: 15765069 No abstract available.
-
Maximizing exclusivity for drug products.Nat Rev Drug Discov. 2005 Sep;4(9):709. doi: 10.1038/nrd1829. Nat Rev Drug Discov. 2005. PMID: 16178117 No abstract available.
-
Eyes on new product development: ophthalmic drug delivery.J Ocul Pharmacol Ther. 2013 Mar;29(2):90-1. doi: 10.1089/jop.2013.1503. J Ocul Pharmacol Ther. 2013. PMID: 23485090 Review. No abstract available.
-
Macro trends in pharmaceutical innovation.Nat Rev Drug Discov. 2005 Jan;4(1):78-84. doi: 10.1038/nrd1610. Nat Rev Drug Discov. 2005. PMID: 15688075 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
